HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Causes of mortality with ticagrelor compared with clopidogrel in acute coronary syndromes.

AbstractOBJECTIVE:
To describe specific causes of death and evaluate whether bleeding events and infection contributed to mortality in all ticagrelor-treated and clopidogrel-treated patients with acute coronary syndromes.
METHODS:
In the PLATelet inhibition and patient Outcomes (PLATO) trial, ticagrelor significantly reduced rates of vascular and total death compared with clopidogrel. In the 905 patients who died postenrolment in the PLATO trial (n=18 624), reviewers, blinded to study treatment, subclassified direct causes of death and evaluated whether infection or bleeding events contributed to fatal events.
RESULTS:
Among vascular deaths, there were significantly fewer sudden deaths (63 (0.7%) vs 98 (1.1%), p<0.01) but no significant difference in deaths caused by acute myocardial infarction (179 (1.9%) vs 194 (2.1%), p=0.43) or heart failure (31 (0.3%) vs 42 (0.5%), p=0.20) with ticagrelor compared with clopidogrel. For non-vascular deaths, there was no difference between treatments in deaths directly caused by infection. Although, patients treated with ticagrelor were at lower risk for death where infection was either a direct cause or contributed to death (51 (0.5%) vs 76 (0.8%), HR 0.67 (0.47 to 0.95), p<0.05) but not for bleeding (42 (0.5%) vs 42 (0.5%), HR 0.99 (0.65 to 1.53), p=0.98).
CONCLUSIONS:
In this post hoc analysis, ticagrelor compared with clopidogrel reduced total and cardiovascular mortality, which appeared to be mainly mediated by a reduction in sudden death. Importantly, bleeding causing or contributing to death did not differ between treatments.
CLINICAL TRIAL REGISTRATION NUMBER:
NCT00391872 (http://www.clinicaltrial.gov).
AuthorsChristoph Varenhorst, Ulrica Alström, Oscar Ö Braun, Robert F Storey, Kenneth W Mahaffey, Maria Bertilsson, Christopher P Cannon, Benjamin M Scirica, Anders Himmelmann, Stefan K James, Lars Wallentin, Claes Held
JournalHeart (British Cardiac Society) (Heart) Vol. 100 Issue 22 Pg. 1762-9 (Nov 2014) ISSN: 1468-201X [Electronic] England
PMID24957530 (Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
CopyrightPublished by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Chemical References
  • Platelet Aggregation Inhibitors
  • clopidogrel
  • Ticagrelor
  • Adenosine
  • Ticlopidine
Topics
  • Acute Coronary Syndrome (diagnosis, drug therapy, mortality)
  • Adenosine (administration & dosage, adverse effects, analogs & derivatives)
  • Age Factors
  • Aged
  • Cause of Death
  • Confidence Intervals
  • Female
  • Follow-Up Studies
  • Humans
  • Kaplan-Meier Estimate
  • Male
  • Middle Aged
  • Platelet Aggregation Inhibitors (administration & dosage, adverse effects)
  • Proportional Hazards Models
  • Prospective Studies
  • Risk Assessment
  • Severity of Illness Index
  • Sex Factors
  • Survival Analysis
  • Ticlopidine (administration & dosage, adverse effects, analogs & derivatives)
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: